Machine learning-based prognostic modeling in gallbladder cancer using clinical data and pre-treatment [F]-FDG-PET-radiomic features.

Objectives: This study evaluates the effectiveness of machine learning (ML) models that incorporate clinical and 2-deoxy-2-[F]fluoro-D-glucose ([F]-FDG)-positron emission tomography (PET)-radiomic features for predicting outcomes in gallbladder cancer patients.

Materials And Methods: The study analyzed 52 gallbladder cancer patients who underwent pre-treatment [F]-FDG-PET/CT scans between January 2011 and December 2021. Twenty-seven patients were assigned to the training cohort between January 2011 and January 2018, and the data randomly split into training (70%) and validation (30%) sets.

Dasatinib and Quercetin as Senolytic Drugs Improve Fat Deposition and Exhibit Antifibrotic Effects in the Medaka Metabolic Dysfunction-Associated Steatotic Liver Disease Model.

Metabolic dysfunction-associated steatotic liver disease (MASLD) causes cellular senescence due to oxidative stress, endoplasmic reticulum stress, and ectopic fat deposition in the liver. Recently, dasatinib, an antitumor agent, and quercetin, a dietary supplement, were combined as a senolytic drug to eliminate senescent cells. Thus, this study aimed to examine the effects of dasatinib and quercetin administration on removing senescent cells and their therapeutic effects on MASLD in a medaka MASLD model.

Platelet-rich plasma-derived extracellular vesicles improve liver cirrhosis in mice.

Introduction: Cirrhosis remains a significant clinical challenge due to its poor prognosis and limited treatment options, creating a high unmet medical need for the development of novel therapies. In this study, we analyzed the effects of a novel approach to treat cirrhosis using platelet-rich plasma-derived extracellular vesicles (PRPEV) in mice.

Methods: PRPEV were collected from platelet-rich plasma using ultrafiltration, and their proteomes were analyzed.

Usefulness of the Primary Tumor Standardized Uptake Value of Iodine-123 Metaiodobenzylguanidine for Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma.

Purpose: To examine the usefulness of semi-quantitative analysis using the standardized uptake value (SUV) of iodine-123 metaiodobenzylguanidine ([I]-MIBG) for predicting metastatic potential in patients with pheochromocytoma (PHEO) and paraganglioma (PGL).

Procedures: This study included 18 PHEO and 2 PGL patients. [I]-MIBG visibility and SUV-related parameters (SUVmax, SUVmean, tumor volume of [I]-MIBG uptake [TV_MIBG], and total lesion [I]-MIBG uptake) were compared with the pathological grading obtained using the Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adrenal Pheochromocytoma and Paraganglioma (GAPP), which are used to predict metastatic potential.